登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>uPAR >SCCHO-ATP152

CHO/Human uPAR Stable Cell Line Development Service

For research use only.

描述(Description)

The CHO/Human c-MET Stable Cell Line was engineered to express the receptor full length human uPAR (Gene ID: 5329), used to mimic cancer target cells. Surface expression of human uPAR was confirmed by flow cytometry.

应用说明(Application)

• Useful for cell-based uPAR binding assay

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puromycin (2 μg/mL)

培养基(Culture Medium)

F-12K + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Receptor Assay

uPAR FACS

Expression analysis of human uPAR on CHO/Human uPAR Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human uPAR Stable Cell Line or negative control cell using PE-labeled anti-human uPAR antibody.

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

Urokinase plasminogen activator surface receptor (U-PAR) is also known as PLAUR, Monocyte activation antigen Mo3, CD antigen CD87. PLAUR contains three UPAR/Ly6 domains. U-PAR is expressed in neurons of the rolandic area of the brain (at protein level) and is also expressed in the brain. PLAUR / CD87 interacts with MRC2, SRPX2 and SORL1. PLAUR / UPAR acts as a receptor for urokinase plasminogen activator and plays a role in localizing and promoting plasmin formation. U-PAR mediates the proteolysis-independent signal transduction activation effects of U-PA.

 

License Disclosure

This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
uPAR靶点信息
英文全称:Urokinase plasminogen activator surface receptor
中文全称:尿激酶型纤溶酶原激活物表面受体
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:5详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定